{"analyses":[{"ciLowerLimit":"-14.6","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"14.6","estimateComment":"Arm A compared with Arm C; normal approximation for confidence interval","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.99","paramType":"Difference between proportions","paramValue":"0.0","statisticalMethod":"Chi-squared"},{"ciLowerLimit":"-17.3","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"9.6","estimateComment":"Arm B compared with Arm C; normal approximation used for confidence interval.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.64","paramType":"Difference between proportions","paramValue":"-3.8","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"9"}],"units":"Participants"}],"description":"Determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. NSCLC: The proportion of patients with response (complete response or partial response according to RECIST) will be compared for each pair-wise comparison of radiotherapy (RT)-containing therapy and control using chi- squared tests. The difference between the proportions responding will be presented with a 90% confidence interval. CRC: The proportion of patients with response will be presented with a 90% exact confidence interval.","groups":[{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high-dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG000","title":"NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low-dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG001","title":"NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.\n\nDurvalumab: Given IV\n\nTremelimumab: Given IV","id":"OG002","title":"NSCLC Arm C (Tremelimumab, Durvalumab)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive high-dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG003","title":"CRC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low-dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG004","title":"CRC Arm B (Tremelimumab, Durvalumab, LD-RT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients receiving at least one regimen of protocol therapy.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}